Traditionally, FTLD, characterized by progressive atrophy of the frontal and temporal lobes of the brain, has been diagnosed only postmortem, limiting clinicians’ ability to tailor treatments during life. The hallmark symptoms of FTLD include marked personality changes, disinhibition, apathy, and language disturbances, which diverge from the memory-centered decline typical of Alzheimer’s disease. The study reveals that when these two pathologies co-exist—a scenario increasingly recognized in neuropathological examinations—it results in a distinct symptomatology, complicating the clinical picture but potentially offering novel diagnostic cues.

Researchers analyzed postmortem data from 919 patients across 29 Alzheimer Disease Research Centers funded by the National Institutes of Health. By focusing on cases confirmed to have intermediate to high levels of Alzheimer’s neuropathology and/or FTLD pathology, the team identified that patients with both disorders manifested neuropsychiatric symptoms reflecting an amalgamation of features from each disease. This represents a paradigm shift from viewing Alzheimer’s and FTLD in isolation toward understanding their combined clinical impact.

Patients diagnosed with both Alzheimer’s and FTLD exhibited increased instances of anxiety, delusions, and irritability compared to those with FTLD alone. Conversely, when contrasted with Alzheimer’s-only patients, those with combined pathology were notably more prone to personality changes and disinhibition, typical FTLD features. This symptomatic overlap highlights a complex neuropsychiatric profile, underscoring the necessity for clinicians to expand their diagnostic frameworks and management plans to accommodate this heterogeneity.

The implications of these findings stretch beyond diagnosis. The co-occurrence of Alzheimer’s and FTLD often precipitates a more rapid and multifaceted decline in patients, challenging caregivers and healthcare providers. Understanding the combined symptom landscape equips medical teams with the foresight to better anticipate disease progression, personalize therapeutic approaches, and allocate resources more effectively for families enduring these illnesses.

Dr. Daliah Ross, the lead author and a postdoctoral fellow in clinical neuropsychology at Brown University’s Warren Alpert Medical School, emphasizes the clinical relevance of symptom tracking. “Recognizing the specific neuropsychiatric symptoms associated with comorbid Alzheimer’s and FTLD can profoundly impact patient management and caregiver support,” she states. Ross envisions a future where symptom-based clinical tools facilitate early and accurate diagnosis, circumventing the current reliance on autopsy for definitive confirmation.

Moreover, co-pathologies compound the difficulty of applying emerging disease-modifying treatments. As new Alzheimer therapies gain momentum, their efficacy in patients with concurrent FTLD pathology remains uncertain. This necessitates dedicated research to dissect therapeutic responses in mixed neuropathology cohorts, avoiding a one-size-fits-all treatment approach which might neglect the nuances of overlapping diseases.

The study’s robust methodology leveraged extensive autopsy-confirmed data, elevating its findings above prior symptom-focused studies reliant solely on clinical diagnosis without neuropathological verification. By correlating observable neuropsychiatric symptoms with concrete pathological substrates, the research delineates a clearer picture of how FTLD influences Alzheimer’s presentation and vice versa.

Dr. Edward Huey, associate director of Brown’s Center for Alzheimer’s Disease Research, highlights an urgent gap in therapeutic options for FTLD. “While Alzheimer’s disease benefits from an expanding repertoire of treatments, FTLD remains devoid of any disease-modifying therapies,” Huey notes. Insights from this study could propel interest and funding towards developing targeted interventions for FTLD, especially in patients exhibiting mixed pathology.

A critical takeaway from this research is the necessity of shifting clinical paradigms. Neurodegenerative diseases rarely manifest in isolation; rather, they often present as a spectrum of overlapping pathologies. This recognition invites a more holistic and integrative approach to diagnosis, research, and treatment development, ultimately improving prognosis and quality of life for affected individuals.

Additionally, caregivers and families receive pragmatic benefits from this research. By better understanding the expected neuropsychiatric trajectory in the presence of dual Alzheimer’s and FTLD pathology, caregivers can better prepare for behavioral challenges and advocate for appropriate supportive services. This knowledge fosters resilience and enhances care strategies, mitigating the grave toll these disorders exact on social and familial networks.

The study, which was partially funded by the National Institute on Aging, sets the stage for a new epoch in neurodegenerative research. It calls upon the scientific community to deepen investigations into mixed dementias, emphasizing the heterogeneity of neuropsychiatric symptoms and their neuropathological underpinnings. Advancing this field not only improves diagnostic accuracy but also catalyzes the creation of therapies tailored to the complex realities of neurodegenerative pathologies.

In summary, this pioneering research from Brown University offers compelling evidence that the coexistence of Alzheimer’s disease and frontotemporal lobar degeneration creates a unique neuropsychiatric profile. Recognizing and diagnosing this comorbidity during life, as opposed to postmortem, marks a crucial step toward personalized medicine in dementia care. With ongoing efforts to disentangle the complex manifestations and treatment responses of mixed pathologies, patients and caregivers alike may await more precise prognoses and eventually, more effective therapeutic interventions.

Subject of Research: People

Article Title: Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration

News Publication Date: 5-Mar-2026

Web References:
https://www.neurology.org/doi/10.1212/WNL.0000000000214750

Keywords: Alzheimer disease, neurodegenerative diseases, frontotemporal lobar degeneration, dementia, neuropsychiatric symptoms, cognitive disorders, medical diagnosis, psychological assessment

Peripheral nerves are uniquely endowed with the remarkable capacity to regrow after damage, often restoring lost function and connectivity. In stark contrast, injuries to the brain or spinal cord result in permanent deficits, a phenomenon that has vexed scientists and clinicians for decades. Understanding why such divergent regenerative responses exist between these two nervous system compartments has become a central quest in neuronal repair research. The recent work led by molecular neurobiologists at the Weizmann Institute of Science, in collaboration with Estonian researchers, sheds light on this very mystery by revealing a previously unappreciated role of certain repetitive DNA elements.

The team focused on short interspersed nuclear elements (SINEs), a class of repetitive sequences that constitute more than ten percent of the human genome. Historically dismissed as “junk DNA,” SINEs have long been pegged as parasitic or functionally inert remnants of evolutionary history. Indrek Koppel, an Assistant Professor at Tallinn University of Technology and co-first author of this study, reflected on this preconception: “SINE elements were considered genomic freeloaders with minimal utility, merely replicating selfishly without benefit to the host. Our research turns this understanding on its head by demonstrating that they produce non-coding RNAs crucial for nerve regeneration.”

Using a combination of advanced molecular biology techniques and experimental nerve injury models in animals, the researchers discovered that peripheral neurons activate the transcription of SINE-derived non-coding RNAs in response to injury. These RNAs do not code for proteins but instead modulate gene expression pathways pivotal for neuronal growth and repair. Intriguingly, this upregulation was tightly correlated with the neurons’ regrowth capacity, establishing a direct link between repeat-element RNA production and functional nerve regeneration.

To probe causality, the team employed targeted molecular interventions to inhibit the production of these SINE-derived RNAs. The results were striking: blocking the RNA synthesis led to a significant decrease in axonal regrowth rates and overall nerve recovery. This definitive evidence underscored that these non-coding RNAs are not mere byproducts but active molecular drivers of repair processes in peripheral neurons.

Having illuminated this mechanism in the peripheral nervous system, the researchers then inquired whether the central nervous system might retain the latent potential for similar RNA-mediated repair. Through clever experimental activation, they artificially induced the production of repeat-element non-coding RNAs in central neurons, which traditionally have virtually no regenerative capacity. Remarkably, an enhancement of neuronal growth and regenerative markers was observed, suggesting that the CNS can be coaxed into initiating repair by harnessing this ancient genomic toolkit.

This revelation offers a paradigm shift in our understanding of the genome’s so-called “dark matter.” The vast tracts of repetitive DNA, previously overlooked as evolutionary detritus, harbor sequences that can be selectively mobilized to orchestrate complex biological responses such as neuronal regeneration. This functional repurposing of genomic repeats paints a more dynamic picture of DNA architecture, where repetitive elements serve as reservoirs of regulatory potential.

From a translational perspective, the implications could be profound. Central nervous system injuries, including spinal cord trauma and stroke, currently lack effective regenerative treatments, leading to lifelong disabilities. By discovering that inducing SINE-derived RNA production enhances CNS regeneration, new molecular therapies aiming to activate these pathways could revolutionize treatment landscapes. Beyond acute injuries, such approaches might also be applicable to chronic neurodegenerative diseases by fostering neuronal resilience and repair.

The study was spearheaded by Professor Mike Fainzilber’s team, who bring extensive expertise in molecular neurobiology and nerve regeneration. The collaboration showcased an impressive blend of cross-disciplinary science, integrating genomics, RNA biology, and neurophysiology to solve a fundamental biological problem with high clinical relevance. Co-first authors Dr. Eitan Erez Zahavi and Dr. Indrek Koppel contributed significantly to experimental design and data analysis, enhancing the study’s robustness.

Future research directions entail delineating the precise molecular pathways through which SINE-derived RNAs exert their regenerative effects. Understanding their interaction with intracellular signaling networks, chromatin remodeling complexes, and other regulatory factors will be critical to harnessing their full therapeutic potential. Additionally, exploring whether similar mechanisms exist in human CNS neurons and devising safe delivery methods for RNA-inducing agents will be crucial next steps toward clinical translation.

This discovery ultimately challenges the long-held dogma that the central nervous system is irreparably limited in its capacity to heal. By unveiling a hidden genomic asset in the form of SINE repeat sequences, scientists have opened a promising avenue for regenerative neuroscience. The integration of repeat-element RNAs into the neuronal growth circuit not only enriches our conceptual framework of gene regulation but also provides hope for patients suffering from devastating nervous system injuries.

The study stands as a testament to the power of revisiting genomic “junk” with fresh eyes and innovative methodologies, revealing treasures of biological function previously concealed. As research continues to unravel the intricate layers of RNA-mediated regulation, therapies built on this knowledge could usher in a new era of nervous system repair and recovery, transforming lives worldwide.

Subject of Research: Animals

Article Title: Repeat-element RNAs integrate a neuronal growth circuit

News Publication Date: 16-May-2025

Web References: http://dx.doi.org/10.1016/j.cell.2025.04.030

References: Zahavi, Eitan Erez et al. Cell, Volume 188, Issue 16, 4350 – 4365.e22

Image Credits: Zahavi, Eitan Erez et al. Cell, Volume 188, Issue 16, 4350 – 4365.e22

Keywords: Peripheral nervous system, central nervous system, nerve regeneration, non-coding RNA, SINE elements, genomic repeats, neuronal growth, neurodegenerative diseases, spinal cord injury, RNA biology